Eric Venker - 23 Dec 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: President & Immunovant CEO
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Issuer symbol: ROIV
Transactions as of: 23 Dec 2025
Net transactions value: -$4,517,747
Form type: 4
Filing time: 29 Dec 2025, 21:00:20 UTC
Previous filing: 11 Dec 2025
Next filing: 14 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Venker Eric	President & Immunovant CEO	C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM	By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker	29 Dec 2025	0001801917

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Options Exercise	$1,208,288	+313,841	+21%	$3.85	1,811,749	23 Dec 2025	Direct
transaction	ROIV	Common Shares	Sale	$4,490,000	-200,000	-11%	$22.45	1,611,749	23 Dec 2025	Direct	F1, F2, F3
transaction	ROIV	Common Shares	Options Exercise	$453,715	+117,848	+7.3%	$3.85	1,729,597	24 Dec 2025	Direct
transaction	ROIV	Common Shares	Sale	$1,689,750	-75,000	-4.3%	$22.53	1,654,597	24 Dec 2025	Direct	F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-313,841	-5.3%	$0.000000	5,562,682	23 Dec 2025	Common Stock	313,841	$3.85	Direct	F5
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-117,848	-2.1%	$0.000000	5,444,834	24 Dec 2025	Common Stock	117,848	$3.85	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an exercise and hold transaction, with a sale of Common Shares only to cover applicable withholding taxes and the exercise price of the stock options exercised.
F2	The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F3	These Common Shares were sold in multiple transactions at prices ranging from $22.25 to $22.64, inclusive.
F4	These Common Shares were sold in multiple transactions at prices ranging from $22.50 to $22.63, inclusive.
F5	Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).